Is B-type natriuretic peptide-guided heart failure management cost-effective?
نویسندگان
چکیده
BACKGROUND Chronic heart failure (CHF) is a common medical problem and B-type natriuretic peptide (BNP)-guided heart failure management for outpatients with symptomatic CHF was found to reduce the readmission rate and mortality, but the costs of treatment may provoke concern in the current cost-conscious clinical setting. METHODS We conducted a cost-effectiveness analysis using a Markov model of regular BNP measurement in the outpatient setting. The target population was symptomatic CHF patients aged 35-85 years recently discharged from the hospital. Intervention was BNP measurement once every 3 months (BNP group) or no BNP measurement (clinical group). Clinical and utility data were retrieved from published studies. Costs were based on published data in the US. Cost-effectiveness was measured by $ per quality-adjusted life year (QALY). RESULTS The baseline analysis during the 9-month period after hospitalization showed the QALY to be longer for the BNP group (0.57 for the BNP group and 0.55 for the clinical group) and the costs were also lower for the BNP group ($9577 and 10,131). The dominance of the BNP group continued during the 1-year follow-up. The incremental costs would be $3491-7787 per QALY. In sensitivity analyses, two parameters with strong effects on the cost-effectiveness were the probability of the first readmission for CHF in the clinical group and the costs for inpatient CHF care. When these two parameters were simultaneously put on the simulation model, the incremental costs of the BNP group may exceed $50,000. CONCLUSIONS Introduction of BNP measurement in heart failure management may be cost-effective.
منابع مشابه
Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure).
OBJECTIVES This study aimed to assess cost-effectiveness of N-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided versus symptom-guided therapy in heart failure (HF) patients ≥60 years old. BACKGROUND Cost-effectiveness of NT-proBNP guidance in HF patients is unclear. It may create additional costs with uncertain benefits. METHODS In the TIME-CHF (Trial of Intensified versus Standard...
متن کاملClinical and Biochemical Assessments of Circulating B-Type Natriuretic Peptide as a Useful Marker in Pediatric Cardiac Patients
Background Although the left ventricle is the major site of BNP secretion in response to cardiac pressure or volume overload, the myocytes of both atria and ventricles secrete B- type natriuretic peptide (BNP). This study aimed to assess and compare the plasma levels of BNP in common pediatric cardiac diseases to clarify its pathophysiological role and evaluate its po...
متن کاملDiagnostic Value of N Terminal Pro B Type Natriuretic Peptide (NT-pro BNP) in Cardiac Involvement in Patients with Beta- Thalassemia
Background Heart failure is a major cause of death in thalassemia. The study aimed to determine the diagnostic value of N Terminal Pro B Type Natriuretic Peptide (NT-pro BNP), to early diagnose the cardiac involvement in beta- thalassemia major patients. Materials and Methods 80 thalassemia patients aged 7 to 18 years old (patients group), and 80 healthy age and gender matched controls were ...
متن کاملNT-proBNP testing A valuable and cost-effective option for the diagnosis and management of heart failure The economic burden of heart failure NT-proBNP testing in the ED Improved diagnosis and stratification of patient care
متن کامل
Cost-utility analysis of nt-probnp-guided multidisciplinary care in chronic heart failure.
OBJECTIVES A recent randomized, controlled trial in chronic heart failure patients showed that NT-proBNP-guided, intensive patient management (BMC) on top of multidisciplinary care reduced all-cause mortality and heart failure hospitalizations compared with multidisciplinary care (MC) or usual care (UC). We now performed a cost-utility analysis of these interventions from a payer's perspective....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- International journal of cardiology
دوره 96 2 شماره
صفحات -
تاریخ انتشار 2004